Faculty, Staff and Student Publications

Publication Date

11-14-2024

Journal

Viruses

Abstract

Glioblastoma (GBM) is the most prevalent malignant brain tumor. Current standard-of-care treatments offer limited benefits for patient survival. Virotherapy is emerging as a novel strategy to use oncolytic viruses (OVs) for the treatment of GBM. These engineered and non-engineered viruses infect and lyse cancer cells, causing tumor destruction without harming healthy cells. Recent advances in genetic modifications to OVs have helped improve their targeting capabilities and introduce therapeutic genes, broadening the therapeutic window and minimizing potential side effects. The efficacy of oncolytic virotherapy can be enhanced by combining it with other treatments such as immunotherapy, chemotherapy, or radiation. Recent studies suggest that manipulating the gut microbiome to enhance immune responses helps improve the therapeutic efficacy of the OVs. This narrative review intends to explore OVs and their role against solid tumors, especially GBM while emphasizing the latest technologies used to enhance and improve its therapeutic and clinical responses.

Keywords

Animals, Humans, Brain Neoplasms, Combined Modality Therapy, Gastrointestinal Microbiome, Glioblastoma, Glioma, Immunotherapy, Oncolytic Virotherapy, Oncolytic Viruses, viroimmunotherapy, therapeutic efficacy, gut microbiome, glioblastoma, combinatory therapies

DOI

10.3390/v16111775

PMID

39599889

PMCID

PMC11599061

PubMedCentral® Posted Date

11-14-2024

PubMedCentral® Full Text Version

Post-print

Published Open-Access

yes

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.